Group 1 - The core point of the news is that Shandong Luxin Qisheng Investment Management Co., Ltd. plans to reduce its holdings in Sanyuan Bio by up to 6 million shares within a specified timeframe, which represents 3% of the total share capital after excluding shares held in the company's repurchase account [1] - The reduction will occur through both centralized bidding and block trading, with a maximum of 2 million shares (1% of total share capital) to be sold via centralized bidding and 4 million shares (2% of total share capital) through block trading [1] Group 2 - Sanyuan Bio was listed on the Shenzhen Stock Exchange's ChiNext board on February 10, 2022, with an initial public offering of 33.721 million shares at a price of 109.30 yuan per share, raising a total of 3.686 billion yuan [2] - The company’s shares reached a peak price of 146.00 yuan on the first day of trading but are currently in a state of decline [2] - The net proceeds from the IPO amounted to 3.547 billion yuan, exceeding the original fundraising target of 900 million yuan by 2.647 billion yuan [2] Group 3 - The total issuance costs for Sanyuan Bio's IPO were 139 million yuan, with underwriting fees accounting for 121 million yuan [3] - In June 2022, the company announced a dividend distribution plan for the 2021 fiscal year, distributing 10 yuan in cash per 10 shares and a bonus of 5 shares for every 10 shares held, increasing the total share capital from 135 million to 202 million shares [3]

证券代码：301206 证券简称：三元生物 公告编号：2025-061 山东三元生物科技股份有限公司 关于股东减持股份的预披露公告 公司股东山东鲁信祺晟投资管理有限公司-山东省鲁信资本市场发展股权投 资基金合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有山东三元生物科技股份有限公司（以下简称"公司"或"三元生物"） 股份 7,920,050 股（占剔除公司回购专用证券账户股份后总股本的 3.96%）的股 东山东鲁信祺晟投资管理有限公司-山东省鲁信资本市场发展股权投资基金合伙 企业（有限合伙）（以下简称"鲁信资本"），计划自本公告披露之日起 15 个交 易日后的 3 个月内（2025 年 8 月 1 日至 2025 年 10 月 31 日）以集中竞价方式和 大宗交易方式合计减持公司股份不超过 6,000,000 股（即不超过剔除公司回购专 用证券账户股份后总股本的 3%）。其中，以集中竞价方式减持本公司股份不超过 2,000,000 股（即不超过剔除公司回购专用证券账户股份 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-060 山东三元生物科技股份有限公司 关于回购公司股份期限届满暨回购完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股），用于后期实施股权激励或员工持股计划。本次回购资金总 额不低于人民币 5,000 万元（含），且不超过人民币 10,000 万元（含），回购价格 不超过 35 元/股（含），回购股份的实施期限自公司董事会审议通过回购股份方 案之日起不超过 12 个月，具体回购股份数量以回购结束时实际回购的股份数量 为准。具体内容详见公司于 2024 年 7 月 9 日和 2024 年 7 月 15 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号： 2024-045）和《回购报告书》（公告编号 ...

Industry Overview - The approval of D-alloheptulose as a new food ingredient aligns with the trend of innovation and upgrading in China's sugar substitute industry, indicating a potential for rapid market penetration in beverages, baking, and confectionery sectors [1][3] - The global market for D-alloheptulose is projected to reach $147.7 million by 2024, with the U.S. market accounting for 30% and an expected compound annual growth rate (CAGR) exceeding 14% from 2025 to 2034 [1] Company Developments - Baolingbao has been involved in the research and development of D-alloheptulose for nearly 10 years and plans to complete a technical transformation project in 2024 with an annual production capacity exceeding 5,000 tons [2] - Shandong Sanyuan Biotechnology has an existing annual production capacity of 10,000 tons of D-alloheptulose and is expanding with a second production line of the same capacity [2] - Jinhe Industrial has an annual production capacity of 1,000 tons of D-alloheptulose, while Shandong Bailong Chuangyuan has recently commenced production of its D-alloheptulose products [2]

Group 1 - The announcement by the National Health Commission regarding the approval of D-Allulose and 20 other "new food" safety assessment materials has led to a surge in the sugar substitute sector, with companies like Baolingbao and Bailong Chuangyuan hitting the daily limit increase [1][2] - D-Allulose is a natural low-calorie sweetener with a sweetness level about 70% that of sucrose, but with only one-tenth the calories, making it a promising alternative to sugar due to its various health benefits [2][3] - The global market for D-Allulose is projected to reach approximately $200 million in 2024 and $500 million by 2030, indicating significant growth potential [2] Group 2 - The approval of D-Allulose in China is expected to reshape the supply chain dynamics, as the market has previously relied heavily on exports, with D-Allulose only being approved in 13 countries including the US and Japan [3][4] - Companies involved in the sugar substitute sector are actively expanding their production capacities, with Baolingbao planning to increase its annual production capacity to over 20,000 tons by 2025, and Jinhe Industrial already having a capacity of 10,000 tons [4][5] - The production of D-Allulose is complex and costly, but companies like Jinhe Industrial are utilizing advanced enzyme technology to reduce production costs and enhance efficiency [4][5]

山东三元生物科技股份有限公司 证券代码：301206 证券简称：三元生物 公告编号：2025-059 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股），用于后期实施股权激励或员工持股计划。本次回购资金总 额不低于人民币 5,000 万元（含），且不超过人民币 10,000 万元（含），回购价格 不超过 35 元/股（含），回购股份的实施期限自公司董事会审议通过回购股份方 案之日起不超过 12 个月，具体回购股份数量以回购结束时实际回购的股份数量 为准。具体内容详见公司于 2024 年 7 月 9 日和 2024 年 7 月 15 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号： 2024-045）和《回购报告书》（公告编号：2024-0 ...

关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301206 证券简称：三元生物 公告编号：2025-058 山东三元生物科技股份有限公司 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日 召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时闲 置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募 资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管理 层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公 司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-057 山东三元生物科技股份有限公司 关于股东减持计划期满暨实施结果的公告 公司股东山东鲁信祺晟投资管理有限公司-山东省鲁信资本市场发展股权投 资基金合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 2 月 21 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减 持股份的预披露公告》（公告编号：2025-021）。山东鲁信祺晟投资管理有限 公司-山东省鲁信资本市场发展股权投资基金合伙企业（有限合伙）（以下简称 "鲁信资本"），计划自上述公告披露之日起 15 个交易日后的 3 个月内（2025 年 3 月 17 日至 2025 年 6 月 16 日）以集中竞价方式和大宗交易方式合计减持公 司股份不超过 6,037,200 股（即不超过剔除公司回购专用证券账户股份后总股本 的 3%）。若减持期间公司有送股、资本公积金 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-056 截至 2025 年 6 月 10 日，公司通过股票回购专用账户以集中竞价交易方式累 计回购公司股份 2,125,700 股，占公司总股本的 1.05%，最高成交价为 30.96 元/ 股，最低成交价为 23.51 元/股，累计成交总金额为 54,917,889.41 元（不含交易 费用）。本次回购进展符合公司回购股份方案及相关法律法规的要求。 二、其他说明 公司回购股份时间、回购股份数量、回购股份价格及集中竞价交易的委托时 段等均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》第十 七条、十八条及公司回购股份方案的相关规定，具体如下： 山东三元生物科技股份有限公司 关于回购公司股份比例达到 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分 ...

Core Insights - The functional sugar industry in China is experiencing a boom driven by national policy support and increasing health consumption demand, but it also faces challenges from international trade tensions and domestic competition [1][5][6] Industry Overview - Yucheng, known as the "Capital of Functional Sugar" in China, produces 35% of the global and 60% of the domestic functional sugar market share, with major companies like Baolingbao and Bailong Chuangyuan leading the industry [2][3] - The city has an annual production capacity of 1.5 million tons of various functional sugar products, leveraging local corn resources for production [2][3] Product Categories - Functional sugars are categorized into three types: functional sugar alcohols, functional dietary fibers, and functional oligosaccharides, with products like erythritol and xylitol being prominent examples [3][4] - New products such as trehalose are being developed for medical applications, including wound healing and vaccine stabilization [3] Market Dynamics - The rise of "zero-sugar" beverages has significantly increased the demand for erythritol, leading to a surge in production capacity that outstripped global demand, resulting in a price drop and industry consolidation [5][6] - Erythritol prices peaked at 40,000 yuan per ton before falling below cost price due to oversupply, leading to financial difficulties for many companies [6] Financial Performance - Companies like Baolingbao and Bailong Chuangyuan are beginning to see a recovery in profits, with Baolingbao reporting a net profit of 110 million yuan in 2024, a 106% increase year-on-year [6] Trade Challenges - The industry faces uncertainties due to anti-dumping investigations in the US and EU, with potential tariffs ranging from 3.29% to 233.3% on Chinese erythritol products [6][7] Strategic Adjustments - Companies are shifting focus to domestic markets while exploring new international markets, adapting their sales strategies to balance domestic and export demands [7] - New product development is a priority, with companies planning to increase production of high-demand products like allulose and tagatose [7][9] Future Outlook - The allulose market is expected to grow significantly, with projections estimating a market size of $200 million in 2024 and $500 million by 2030 [8][9] - Companies are actively expanding their allulose production capacities, anticipating regulatory approvals for new products in the near future [9][10]